Biocure Announces the Appointment of a New Director


Biocure Technology Inc. (CSE:CURE) (OTC:BICTF) (“CURE” or the “Company”) is pleased to announce that effective of today’s date, Mr. Danny Joh has been appointed as a director of Biocure Technology Inc.

Biocure Technology Inc. (CSE:CURE) (OTC:BICTF) (“CURE” or the “Company”) is pleased to announce that effective of today’s date, Mr. Danny Joh has been appointed as a director of Biocure Technology Inc.

After completing a PhD in Biochemistry at Texas A&M university and an MBA at Rice University, Danny Joh moved to the San Francisco area to build a career in the biopharma industry. For twenty years, he has expanded his biopharma product development and cross-functional program management experiences while working for major biopharma companies, including Chiron, Genentech, Biomarin, Sangamo and other biotech companies in the San Francisco area. His experience spans from early to late stage product development in various platforms, including biologics, small molecules, and gene therapy across many therapeutic areas, including cancer and rare genetic disorders. He is a welcomed addition to our seasoned team of Management and brings a wealth of experience to our Board.

About Biocure

Biocure is a South Korean based Bio Pharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. Biocure is in the process of pre-clinical trials of five major biosimilar products in South Korea, including Interferon Beta 1b, PEG-Filgrastim and Ranibizumab as well as CAR-T Cell Therapy. Interferon Beta 1b is used for treating relapsing forms of multiple sclerosis (“MS”) Filgrastim is used to treat neutropenia, a lack of certain white blood cells caused by bone marrow transplants, chemotherapy, and other conditions. Ranibizumab is used for treating macular degeneration. It is also used to treat a type of eye problem known as macular edema, as well as certain eye problems caused by diabetes. Biocure is also developing a foot and mouth disease vaccine, a hair growth production product and a breast cancer detection kit.


/s/ “Sang Mok Lee”
CEO and Director

For further information, please contact:
Biocure Technology Inc. Telephone: 604-609-7146, or

Certain statements in this news release, which are not historical in nature, constitute “forward looking statements” within the meaning of that phrase under applicable Canadian securities law. These statements include, but are not limited to, statements or information concerning the Company’s proposed activities under the Agreement and the expectations of the Company regarding funding payments due pursuant to the Agreement. These statements reflect management’s current assumptions and expectations and by their nature are subject to certain underlying assumptions, known and unknown risks and uncertainties and other factors which may cause actual results, performance or events to be materially different from those expressed or implied by such forward looking statements. Except as required pursuant to applicable securities laws, the Company will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by the Company. Readers are cautioned not to place undue reliance on forward looking statements. Neither the Canadian Securities Exchange (the “CSE”) nor the Investment Industry Regulatory Organization of Canada) accepts responsibility for the adequacy or accuracy of this release.

Click here to connect with Biocure Technology Inc. (CSE:CURE, OTC:BICTF) for an Investor Presentation.

The Conversation (0)


S&P 5004206.94+1.49


Heating Oil2.28-0.08
Natural Gas2.31-0.10